| Cost-effectiveness of sunitinib in metastatic renal cell carcinoma - Abstract - UroToday |
|
|
UroToday Sunitinib is one of the first targeted treatments for metastatic renal cell carcinoma (mRCC) and is currently considered as the standard of care for most of the mRCC patients in the first-line setting. The introduction of targeted treatments has, |